Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Rimonabant28 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A03803 | 33860199 | ACS Pharmacol Transl Sci | Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A11942 | 30673308 | Can J Physiol Pharmacol | The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease. | 2019 | Details |
| A15687 | 28759733 | Can J Physiol Pharmacol | Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin. | 2017 | Details |
| A15798 | 28705172 | BMC Endocr Disord | Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. | 2017 | Details |
| A16481 | 28363784 | Chem Phys Lipids | The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease. | 2017 | Details |
| A18539 | 27063274 | Clin Liver Dis | Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A20218 | 26078820 | Oxid Med Cell Longev | Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A21321 | 25406988 | Lipids Health Dis | Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model. | 2014 | Details |
| A23682 | 23567085 | J Hepatol | Cannabinoid signaling and liver therapeutics. | 2013 | Details |
| A23813 | 23452341 | Br J Clin Pharmacol | The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake. | 2014 | Details |
| A25718 | 21510837 | Curr Top Med Chem | A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. | 2011 | Details |
| A26364 | 20584230 | Int J Clin Pract | Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26437 | 20460921 | Dig Dis | Endocannabinoids and their role in fatty liver disease. | 2010 | Details |
| A26478 | 20415685 | Diabetes Obes Metab | The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. | 2010 | Details |
| A26771 | 19818116 | BMC Gastroenterol | Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. | 2009 | Details |
| A27218 | 18956296 | Semin Liver Dis | Current and emerging therapies in nonalcoholic fatty liver disease. | 2008 | Details |
| A33105 | 26681496 | Biol Psychiatry | Cannabinoid Transmission in the Hippocampus Activates Nucleus Accumbens Neurons and Modulates Reward and Aversion-Related Emotional Salience. | 2015 | Details |
| A37142 | 19858584 | Saudi J Gastroenterol | Endocannabinoids and non-alcoholic steatohepatitis. | 2009 | Details |
| A44806 | 27256522 | Clin Endocrinol (Oxf) | Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. | 2016 | Details |
| A45807 | 22646861 | Expert Opin Drug Discov | Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. | 2011 | Details |
| A46011 | 21564446 | Int J Clin Pract | Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. | 2011 | Details |
| A46425 | 18772330 | Am J Pathol | Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. | 2008 | Details |
| A46503 | 18209783 | Can J Gastroenterol | Obesity: a review of pathogenesis and management strategies. | 2008 | Details |
| A48273 | 17845546 | Liver Int | Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. | 2007 | Details |
| A52815 | 21386801 | Int J Obes (Lond) | Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. | 2011 | Details |
| A52961 | 18773755 | G Ital Cardiol (Rome) | [Pharmacological therapy of obesity]. | 2008 | Details |
| A52976 | 18426509 | J Neuroendocrinol | Dysregulation of the endocannabinoid system in obesity. | 2008 | Details |